PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ)
$150.7 0.11 (0.073%)
Analysed PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ) News Sources
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates
30-07-2026
yahoo.com
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
07-08-2026
yahoo.com
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
11-08-2026
yahoo.com
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
11-08-2026
yahoo.com
J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead
24-08-2026
yahoo.com
Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says
11-08-2026
yahoo.com
Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued
09-07-2026
yahoo.com
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
05-08-2026
yahoo.com
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates
05-08-2026
yahoo.com
Protagonist Therapeutics Reports Granting of Inducement Awards
18-08-2026
yahoo.com
What is the current price of PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ)?
The current price of PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ) is $150.7.
PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ) absolute price change since previous trading day?
The absolute price change of PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ) since the previous trading day is $0.11.
PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ) percentage price change since previous trading day?
The percentage price change of PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ) since the previous trading day is 0.073%.
What is the most recent average sentiment score for PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ)?
The most recent average sentiment score for PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ) is 60 out of 100.
What is the most recent average sentiment for PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ)?
The most recent sentiment for PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ) is .
SEC-8K** Filing Available For PROTAGONIST THERAPEUTICS INC (PTGX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.